Trials / Completed
CompletedNCT02774005
Study to Assess the Efficacy and Safety of Raxone in LHON Patients
External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 199 (actual)
- Sponsor
- Santhera Pharmaceuticals · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
LEROS is an open-label interventional Phase IV study, designed to further assess the efficacy and safety of Raxone® in the long-term treatment of LHON patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idebenone |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2021-03-29
- Completion
- 2021-03-29
- First posted
- 2016-05-16
- Last updated
- 2023-04-21
- Results posted
- 2023-04-21
Locations
29 sites across 10 countries: United States, Austria, Belgium, Bulgaria, Germany, Italy, Poland, Portugal, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02774005. Inclusion in this directory is not an endorsement.